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    1.INTRODUCTION 
The thyroid gland and the heart share a close relationship arising in 
embryology. In ontogeny the thyroid and heart anlage migrate together. The 
close physiological relationship is affirmed by predictable changes in 
cardiovascular function across the entire range of thyroid disease states.  
In fact, cardiovascular manifestations are some of the most common 
and characteristic findings of hyperthyroidism. In a tropical country like 
India where the iodine deficiency status is proficient, hypothyroidism 
silently exerts its morbid effects in a large group of populations. As per an 
extrapolated statistics published by American Medical Women Association 
there are 78,314,013 cases, out of 1,065,070,607 studied populations in 
India. 
Where Pediatricians worry about the mental status of children and 
Obstetricians worry about the menstrual irregularities and infertility caused 
by hypo and hyperthyroidism, Physicians and Cardiologists started worrying 
about the adverse cardiovascular effects of thyroid deficiency and excess.    
   According to one study from AIIMS (All India Institute of Medical 
Sciences), in India about 40 million people are suffering from thyroid 
disorders. In one hand the urbanization and changes in lifestyle increase the 
cardiovascular morbidity and mortality in younger populations, the current 
threat is sub clinical hypothyroidism and its adverse effects on 
cardiovascular system.  
  Not only by its atherogenic effect over the blood vessels and lipid 
profile, but also through so many different effects on the  heart and 
hemodynamics, hypothyroidism has increased the cardiovascular morbidity 
and mortality.  
Hyperthyroidism is an arrythmogenic state and it also exerts various 
functional and anatomical effects in the CVS. 
   Lack of large population study regarding the cardiovascular morbidity 
in thyroid disorders and lack of awareness of hyper and hypothyroidism 
among undereducated people give way for thyroid disorders to  manipulate 
various systems silently long before they come to light. 
So, hypothyroidism or hyperthyroidism can primarily cause so many 
systemic manifestations or they act as worst co morbid conditions with other 
CVS disorders. 
One interesting point to bear in mind is not only the thyroid disorders 
affect the heart but the drugs used to treat arrhythmias like Amiodarone can 
also adversely affect the thyroid status. 
Some special situations like pregnancy, CCF and CRF are all put forth 
an extra burden over thyroid and a vicious cycle may set in.  
Early observations of the heart in hyperthyroidism emphasize the 
similarity to that of hyperadrenergic states and moreover propose enhanced 
sensitivity to catecholamines in this setting. This postulate forms the basis 
for the test described by Goetsch in 1918 in which hyperthyroidism could 
be diagnosed by demonstrating a marked cardio acceleration and blood 
pressure response to small, subcutaneous doses of epinephrine. Hyperthyroid 
subjects have decreased circulating catecholamine concentrations despite the 
appearance of increased adrenergic signs and symptoms. 
The role of physician in this multidisciplinary approach is to mainly 
concentrate on the cardiovascular morbidity while treating or correcting the 
thyroid aberrancy. 
Though being protected from major coronary events prior to 
menopause, where females outnumber males in having thyroid disorders, 
which toggles the protective effect of estrogen. This is how   one hormone 
influences the protective effect of the other. 
The molecular biology astonishingly throws light over many of the 
hidden mechanisms, the primary and secondary role of thyroid hormone and 
the resultant pathophysiology in excess and deficient status of the same 
hormone are explored in full. Moreover early detection of thyroid 
dysfunction accurately by RIA (Radio Immuno Assay) and other techniques 
made the iceberg to come to the surface. 
N.Kochupillai, an eminent Endocrinologist from All India Institute of 
Medical Sciences (AIIMS), states that tropical countries should try to 
eliminate the iodine deficiency by redirecting the Health Resources, so as to 
reduce the resultant hypothyroidism and its hemodynamic burden.   
  
 
 
 
 
 
 
 
 
 
 
 
 
                  
               2. REVIEW OF LITERATURE 
To identify and manage thyroid hormone mediated cardiac disease 
states, it is important to understand the cellular mechanisms of thyroid 
hormone on the heart and vascular smooth muscle cells [2]
2.1.0 CELLULAR MECHANISMS OF THYROID HORMONE              
ACTION  
2.1.1 Regulation of thyroid hormone synthesis and action
Under the regulation of thyroid stimulating hormone (thyrotropin, 
TSH), the thyroid gland has the unique property of concentrating serum 
iodide and through a series of enzymatic steps synthesizes predominantly 
tetraiodothyronine (T4 85 percent) and a smaller percentage of 
triiodothyronine (T3 15 percent).[3] The major source of T3 synthesis is by 
conversion by 5′ monodeiodination primarily in the liver and to a lesser 
degree in the kidney.[4] A variety of studies have confirmed T3 as the active 
form of thyroid hormone that accounts for the vast majority of biological 
effects including stimulation of tissue thermogenesis, alterations in the 
expression of various cellular protein, and actions on the heart and vascular 
smooth muscle cells. [2] [6] 
 Serum-free T3 in turn is taken up by a process of facilitated diffusion 
within cells, where it appears to pass without additional protein binding to 
the cell nucleus. Most data indicate that the cardiac myocyte cannot 
metabolize T4 to T3. Therefore despite the presence of the relevant enzymes, 
all of the observed nuclear actions and changes in gene expression result 
from changes in blood levels of T3.  
2.1.2Thyroid hormone Receptors (TRs)in the Myocytes 
The cardiac myocyte expresses both the alpha and beta isoforms of 
the thyroid hormone receptors (TRs), which arise from two separate genes. 
These genes give rise to splice variants TRalpha1 and TRalpha2, of which 
only the former binds thyroid hormone, as well as TRbeta1, TRbeta2, and 
TRbeta3.[5] 
 As reported for the steroid and retinoic acid family of receptor 
proteins, the TRs act by binding as either homodimers or heterodimers to the 
thyroid hormone response elements (TREs) in a promoter region of specific 
genes.[5] Binding to the promoter regions can either activate or repress gene 
expression. [6] 
2.1.3 Molecular mechanism of thyroid hormone action on heart 
Thyroid hormone transcriptionally regulates many cardiac proteins. 
They include structural and regulatory proteins, as well as a variety of 
cardiac membrane ion channels and cell surface receptors, thus providing a 
molecular mechanism to explain many of the diverse effects of thyroid 
hormone on the heart. The first reported and the best studied to date has been 
the myosin heavy chain isoforms alpha and beta). The human ventricle 
expresses primarily beta myosin, and there appear to be few, if any, 
alterations in isoform expression accompanying thyroid disease states.  
Changes in myosin heavy chain isoform expression occur in the 
human atria in a variety of disease states including congestive heart failure, 
and whether these changes are thyroid hormone mediated remains to be 
determined.[7]
The sarcoplasmic reticulum calcium-activated ATPase is an important 
ion pump that determines the magnitude of myocyte calcium cycling. The 
reuptake of calcium into the sarcoplasmic reticulum early in diastole in part 
determines the rate at which the left ventricle relaxes (isovolumetric 
relaxation time, IVRT).[1] The activity of SERCA2 in turn is regulated by the 
polymeric protein phospholamban with its ability to inhibit SERCA activity 
further modified by the level of phosphorylation of the individual 
phospholamban monomers.[8] Inotropic agents that enhance cardiac 
contractility through increases in myocyte cAMP do so by stimulating the 
phosphorylation of phospholamban. Thyroid hormone inhibits the 
expression of phospholamban and increases phospholamban 
phosphorylation.[9] 
 Thyroid hormone exerts most of its direct effects on cardiac 
contractility by regulating calcium cycling through the SERCA-
phospholamban system both transcriptionally and posttranscriptionally. This 
molecular mechanism can explain why diastolic function varies inversely 
across the entire spectrum of thyroid disease states including even mild, 
subclinical hypothyroidism. [2] [11]  
Changes in other myocyte genes including Na+/K+ ATPase account 
for the increase in basal oxygen consumption of the experimental 
hyperthyroid heart and explain the decrease in digitalis sensitivity of 
hyperthyroid patients. A variety of studies have shown that thyroid hormone 
can regulate the genetic expression of its own nuclear receptors within the 
cardiac myocyte. 
2.1.4 Nongenomic mechanisms of thyroid hormone action 
In addition to the well-characterized nuclear effects of thyroid 
hormone, a growing body of cardiac responses to thyroid hormone appear to 
be mediated through nongenomic mechanisms[12] as suggested by their 
relatively rapid onset of action (faster than can be accounted for by changes 
in gene expression and protein synthesis) and failure to be affected by 
inhibitors of gene transcription. The significance of these diverse actions 
remains to be established but may explain the ability of acute T3 treatment to 
alter cardiovascular hemodynamics. They may alter the functional properties 
of membrane ion channels and pumps including the sodium channel and the 
inward rectifying potassium current (Ik). 
2.2.0 THYROID FUNCTION TESTING  
A number of sensitive and specific laboratory tests can establish a 
diagnosis of thyroid disease with a high degree of precision. Serum TSH is 
the most widely used and most sensitive measure for the diagnosis of both 
hypothyroidism and hyperthyroidism. [13] Serum TSH levels uniformly 
increase (>5 mIU/ml) in patients with primary hypothyroidism, and 
conversely, because of the normal feedback of excess levels of T4 (and T3) 
on the pituitary synthesis and secretion of TSH, the levels are low (<0.04 to 
0.01 mIU/ml) in hyperthyroidism. Measures of free T4 can be useful when 
coexistent hepatic, nutritional, or genetic disease may alter thyroxine-
binding globulin content. Autoimmune thyroid disease (Hashimoto and 
Graves) can be further diagnosed by the use of serologic measures of 
antithyroid antibodies, most specifically antithyroid peroxidase (anti-TPO) 
or antithyroglobulin antibodies. 
2.3.0 THYROID HORMONE–CATECHOLAMINE INTERACTION  
Early observations of the heart in hyperthyroidism emphasize the 
similarity to that of hyperadrenergic states and moreover propose enhanced 
sensitivity to catecholamines in this setting. Increased beta1 adrenergic 
receptors on cardiac myocytes observed in experimental hyperthyroidism 
provide a mechanism for enhanced catecholamine sensitivity. A recent 
carefully controlled study of subhuman primates, however, found no 
increase in sensitivity of the heart or cardiovascular system to 
catecholamines in experimental hyperthyroidism.[14]  
Accompanying the increased levels of beta1-adrenergic receptors and 
guanosine triphosphate binding proteins, thyroid hormone decreases the 
expression of cardiac-specific (V, VI) adenylyl cyclase catalytic subunit 
isoforms and thereby maintains cellular response to beta-adrenergic agonists 
within normal limits.  
 
Table 2.1-- Thyroid Hormone Regulation of Cardiac Gene Expression 
Positively Regulated Negatively Regulated 
Alpha-myosin heavy chain Beta-myosin heavy chain 
Sarcoplasmic reticulum Ca2+ -ATPase Phospholamban 
Na+, K+ -ATPase Na+/Ca2+ exchanger 
Voltage-gated potassium channels (Kv1.5, 
Kv4.2, Kv4.3) 
Thyroid hormone receptor 
alpha1 
Atrial and brain natriuretic peptide Adenylyl cyclase (AC) types 
V, VI 
Malic enzyme 
Beta-adrenergic receptor 
Guanine nucleotide–binding 
protein Gi
 
 2.4.0 Hemodynamic Alterations in Thyroid Disease  
Changes in myocardial contractility and cardiovascular 
hemodynamics occur across the entire spectrum of thyroid disease.[11] 
2.4.1 Effects of T3 on heart and vascular smooth muscle 
Multiple studies including those in experimental animals, as well as 
invasive and noninvasive measurements in patients, indicate that 
triiodothyronine regulates cardiac inotropy and chronotropy through a 
variety of both direct and indirect mechanisms. [12] [17] Direct effects on 
vascular smooth muscle cells decrease systemic vascular resistance of the 
arterioles of the peripheral circulation. [17] [20] A decrease in mean arterial 
pressure and activation of the renin-angiotensin-aldosterone system occurs, 
as does an increase in renal sodium reabsorption. The increase in plasma 
volume coupled with an increase in erythropoietin leads to an increase in 
blood volume and a rise in cardiac preload.[18] 
 Thus a combination of lower systemic vascular resistance (by as 
much as 50 percent), coupled with increases in venous return and preload, 
increases cardiac output.  
 TABLE2. 2- Cardiovascular Changes with Thyroid Disease 
Parameter Normal Hyperthyroid Hypothyroid
Systemic vascular resistance 
(dyne-cm · sec-5) 
1500-
1700 
700-1200 2100-2700 
Heart rate (beats/min) 72-84 88-130 60-80 
Cardiac output (liter/min) 5.8 >7.0 <4.5 
Blood volume (% of normal) 100 105.5 84.5 
 
Triiodothyronine appears to reduce systemic vascular resistance by 
both direct effects on vascular smooth muscle cells and through changes in 
the vascular endothelium potentially involving the synthesis and secretion of 
nitric oxide.[16] Thus the combination of increased cardiac output and 
decreased arterial compliance, which may be more pronounced in older 
patients with some degree of arterial vascular disease, leads to systolic 
hypertension in up to 30 percent of patients.[17] 
 
 
2.4.2 Hemodynamic alterations in hypothyroidism 
In hypothyroidism, systemic vascular resistance may increase as much 
as 30 percent. Mean arterial pressure rises with up to 20 percent of patients 
having significant diastolic hypertension.[17] Even mild hypothyroidism may 
decrease endothelial-derived relaxing factors.[21] The diastolic hypertension 
of hypothyroidism is frequently associated with a low renin level and a 
decrease in hepatic synthesis of renin substrate. This leads to a 
characteristically low level of salt sensitivity, again reinforcing the 
importance of an increase in systemic vascular resistance underlying the 
mechanism for diastolic hypertension.[22] 
2. 5.0Hemodynamic alterations in Hyperthyroidism  
2.5.1 Exercise Intolerance 
Cardiovascular symptoms are an integral and often the predominant 
clinical presentation of patients with hyperthyroidism. Palpitations resulting 
from both an increase in the rate and force of cardiac contractility are present 
in the majority of patients. The increase in heart rate results from both an 
increase in sympathetic tone and a decrease in parasympathetic stimulation. 
Heart rates >90 beats per minute both at rest and during sleep commonly 
occur, the normal diurnal variation in heart rate is blunted and the increase 
during exercise is exaggerated. 
 Many hyperthyroid patients experience exercise intolerance and 
exertional dyspnea, due in part to weakness in skeletal and respiratory 
muscle. [2] [24] In the setting of a low vascular resistance and increased 
preload, cardiac functional reserve is compromised and cannot further rise to 
accommodate the demands of submaximal or maximal exercise.[23]  
2.5.2-Chestpain in thyrotoxicosis 
Patients can experience angina-like chest pain. In older patients with 
known or suspected coronary artery disease, the increase in cardiac work 
associated with the increase in cardiac output and cardiac contractility of 
hyperthyroidism can produce myocardial ischemia, which can respond to 
beta-adrenergic blocking agents or the restoration of a euthyroid state. 
 In rare patients, usually younger women, there is a syndrome of chest 
pain at rest associated with ischemic ECG changes. Cardiac catheterization 
has demonstrated that the majority of these patients have angiographically 
normal coronary arteries; however, coronary vasospasm has been reported 
similar to that found in variant angina. Myocardial infarction rarely 
develops, and these patients appear to respond to calcium channel blockers 
or to nitroglycerin. 
2.5.3 PHT in Thyrotoxicosis 
Recent reports have shown that hyperthyroidism is associated with a 
significant degree of pulmonary hypertension (pulmonary artery systolic 
pressure >75 mm Hg), which was reversible after treatment of the Graves 
disease. This observation implies that although systemic vascular resistance 
is decreased with thyrotoxicosis, peripheral vascular resistance is not. 
Perhaps all patients with unexplained pulmonary hypertension should be 
evaluated for thyroid disease with measurement of serum TSH. [18] [25] 
2.6.0 Atrial fibrillation and Hyperthyroidism 
The most common rhythm disturbance in patients with 
hyperthyroidism is sinus tachycardia.[3] Its clinical impact, however, is 
overshadowed by patients with atrial fibrillation resulting from 
thyrotoxicosis. The prevalence of atrial fibrillation and the less common 
forms of supraventricular tachycardia in this disease ranges from 2 to 20 
percent. [26] [27] When compared with a control population with normal 
thyroid function and a prevalence of atrial fibrillation of 2.3 percent, the 
prevalence of atrial fibrillation in overt hyperthyroidism was 13.8 percent.[26] 
In a study of more than 13,000 hyperthyroid patients, the prevalence rate for 
atrial fibrillation was less than 2 percent, perhaps because of earlier 
recognition and disease treatment. When that same group of patients was 
analyzed for age distribution, it was seen that there was a stepwise increase 
in prevalence in each decade peaking at approximately 15 percent in patients 
older than 70 years.[25] This latter study confirms essentially all reports that 
atrial fibrillation caused by hyperthyroidism is more common with 
advancing age. Thus the yield of abnormal thyroid function testing including 
a low serum TSH appears to be low in patients with new-onset atrial 
fibrillation. However, the ability to restore thyrotoxic patients to a euthyroid 
state and sinus rhythm justifies TSH testing in most patients with the recent 
onset of otherwise unexplained atrial fibrillation. 
Treatment of atrial fibrillation in the setting of hyperthyroidism 
includes beta-adrenergic blockade using one of a variety of beta1 selective or 
nonselective agents to control the ventricular response. This symptomatic 
measure can be accomplished rapidly, whereas the treatments leading to 
restoration of the euthyroid state require more time. Anticoagulation in 
patients with hyperthyroidism and atrial fibrillation is controversial. [22] [28]  
The potential for systemic or cerebral embolization must be weighed against 
the risk of bleeding and complications related to this therapy.  
Successful treatment of hyperthyroidism with either radioiodine or 
antithyroid drugs and restoration of normal serum levels of T4 and T3 are 
associated with reversion to sinus rhythm in two thirds of patients within 2 
to 3 months. [25] 
In older patients or in the setting of atrial fibrillation of longer 
duration, the rate of reversion to sinus rhythm is lower and therefore 
electrical or pharmacological cardioversion should be attempted, but only 
after the patient has been rendered euthyroid.  
2.7.0 HEART FAILURE AND HYPERTHYROIDISM 
The cardiovascular alterations in hyperthyroidism include increased 
resting cardiac output and enhanced cardiac contractility. Nevertheless, a 
minority of patients present with symptoms including dyspnea on exertion, 
orthopnea, and paroxysmal nocturnal dyspnea, as well as signs 
demonstrating peripheral edema, neck vein distention, and an S3 indicative 
of heart failure. This complex of findings coupled with a failure to increase 
the LV ejection fraction with exercise has suggested the possibility of a 
hyperthyroid cardiomyopathy.  
The term often used in this setting—high output failure—is not 
appropriate because although resting cardiac output is as much as two to 
three times normal, the exercise intolerance does not appear to be a result of 
cardiac failure but rather of skeletal muscle weakness. [2] [24] High output 
states, however, can increase renal sodium reabsorption, expand plasma 
volume, and cause development of peripheral edema, pleural effusions, and 
venous hypertension. Interestingly, whereas systemic vascular resistance 
falls with hyperthyroidism, the pulmonary vascular bed is not similarly 
affected and, as a result of the increase in output to the pulmonary 
circulation, there is an increase in pulmonary artery pressures. [18] [25] This 
results in a rise in mean venous pressure, neck vein distention, hepatic 
congestion, and peripheral edema of the type associated with primary 
pulmonary hypertension or right heart failure. [2] [18] [25]
Patients with longstanding hyperthyroidism and marked sinus 
tachycardia or atrial fibrillation can develop low cardiac output, impaired 
cardiac contractility with a low ejection fraction, an S3 and pulmonary 
congestion, all consistent with congestive heart failure.[1] Review of such 
cases suggests that impairment in left ventricular function results from 
prolonged high heart rate and the development of rate-related heart failure. 
When the left ventricle becomes dilated, mitral regurgitation may also 
develop. Recognition of this entity is important because treatments aimed at 
slowing heart rate or controlling the ventricular response in atrial fibrillation 
appear to improve left ventricular function even before initiation of 
antithyroid therapy.[1] 
 Because these patients are critically ill they should be managed in an 
intensive care unit setting. Some patients with hyperthyroidism (similar to 
the overall congestive heart failure population) do not tolerate initiation of 
beta-adrenergic blocking drugs in full doses, and treatment can be started 
with lower doses of short-acting beta-blocking drugs in conjunction with 
classic forms of treatment of acute congestive heart failure including 
diuresis. 
The increase in rate-pressure product and oxygen consumption that 
results from hyperthyroidism can impair cardiac function in older patients 
with known or suspected ischemic, hypertensive, or valvular heart disease.  
 
TREATMENT  
Treatment of patients with thyrotoxic cardiac disease should include a 
beta-adrenergic antagonist to lower the heart rate to 10 or 15 percent above 
normal. This will cause the tachycardia-mediated component of ventricular 
dysfunction to improve, whereas the direct inotropic effects of thyroid 
hormone will persist.[1] The rapid onset of action and the improvement in 
many of the signs and symptoms of hyperthyroidism indicate that most 
patients with overt symptoms should receive beta-blocking agents. 
Definitive therapy can then be accomplished safely with iodine-131 alone or 
in combination with an antithyroid drug. 
2.8.0 HYPOTHYROIDISM  
In contrast to the dramatic clinical signs and symptoms of 
hyperthyroidism, the cardiovascular findings of hypothyroidism are more 
subtle.[31] Mild degrees of bradycardia, diastolic hypertension, a narrow 
pulse pressure and a relatively quiet precordium, and decreased intensity of 
the apical impulse are characteristic.  
2.8.1 Hemodynamic changes in hypothyroidism 
Hemodynamic changes of hypothyroidism are diametrically opposite 
to that of hyperthyroidism and explain many of the physical findings. 
Despite the decrease in cardiac output and contractility of the hypothyroid 
myocardium, recent studies of myocardial metabolism by PET scan have 
shown energy inefficiency of the hypothyroid myocardium.  
The oxygen cost of work increases primarily as a result of the increase 
in afterload.[32] Treatment of hypothyroid patients with the restoration of a 
euthyroid state resolves these changes in parallel with a return of systemic 
vascular resistance to lower levels. [32] [33]
2.8.2 Changes in Lipid profile 
Hypothyroidism also produces increases in total and low-density 
lipoprotein (LDL) cholesterol in proportion to the rise in serum TSH.[33] 
Although thyroid hormone can alter cholesterol metabolism through 
multiple mechanisms including a decrease in biliary excretion, it appears 
that changes in LDL metabolism caused by decreases in LDL receptor 
number are a primary mechanism. [35] [36] 
2.8.3 Pericardial effusion in Hypothyroidism 
Pericardial effusions can occur consistent with observation that 
patients with hypothyroidism have an increase in volume of distribution of 
albumin and a decrease in lymphatic clearance function. Occasionally the 
pericardial effusions are quite large, causing the appearance of cardiomegaly 
on chest radiograph. Although rare, tamponade with hemodynamic 
compromise can occur. Echocardiography demonstrates small to moderate 
effusions in up to 30 percent of overtly hypothyroid patients, which resolve 
over a period of weeks to months after initiation of thyroid hormone 
replacement.[31]
2.8.4 ECG in Hypothyroidism 
As a result of changes in ion channel expression, the ECG in 
hypothyroidism is characterized by sinus bradycardia, low voltage, and 
prolongation of the action potential duration and the QT interval. The 
latter in turn predisposes the patients to ventricular arrhythmias, and cases of 
patients with acquired torsades de pointes that have improved or 
completely resolved with hormone replacement have been reported. (31)
 2.8.5 CAD risk in Hypothyroidism 
As a result of increases in risk factors including hypercholesterolemia, 
hypertension, and elevated levels of homocysteine, patients with 
hypothyroidism may have increased risk for atherosclerosis and coronary 
and systemic vascular disease. [34] [35] Recent studies have shown increases in 
abdominal aortic atherosclerosis in elderly women patients with even mild 
hypothyroidism.[36]  
Whether patients with hypothyroidism have an increase in coronary 
artery disease is an important clinical issue. Recent findings suggest 
increased cardiovascular morbidity and mortality with untreated subclinical 
hypothyroidism.[37] Noninvasive studies including thallium scanning have 
demonstrated abnormalities in perfusion suggestive of myocardial ischemia, 
but these defects appear to resolve with thyroid hormone treatment. 
In patients younger than 50 years of age with no history of heart disease, it is 
possible to initiate full replacement doses of l-thyroxine (100 mg to 150 mg 
per day) without concern for untoward cardiac effects. In patients older than 
age 50 with known or suspected coronary artery disease, the issue is more 
complicated.  
2.9.0 DIAGNOSIS  
Hashimoto disease, postradioiodine therapy for Graves disease, and 
iodine deficiency (in parts of the world where that remains a public health 
problem) are the leading causes of hypothyroidism and produce diagnostic 
elevation in serum TSH.[13] Thus the finding of an elevated TSH is sufficient 
to establish the diagnosis and form the basis for treatment. In routine 
practice additional testing with a serum T4 and T3 resin uptake is 
confirmatory.  
The prevalence of hypothyroidism is estimated at 3 to 4 percent for 
overt disease and 7 to 10 percent for the milder forms of disease. Thus TSH 
screening can be advised for all adults and particularly in patients with 
hypertension, hypercholesterolemia, hypertriglyceridemia, coronary or 
peripheral vascular disease, and unexplained pericardial or pleural effusions 
and for a variety of musculoskeletal syndromes or statin-associated 
myopathy. [4] [40]
2.10.0 TREATMENT  
The response to treatment of hypothyroidism is predictable, especially 
from a cardiovascular perspective. Stepwise thyroid hormone replacement 
using levothyroxine sodium (Levoxyl, Synthroid) incrementally decreases 
serum TSH, serum cholesterol, and serum creatine kinase and improves left 
ventricular performance. Full replacement is accomplished when serum TSH 
is normal.[13] In the rare condition of myxedema coma, which is 
characterized by patients with severe and longstanding hypothyroidism who 
develop hypothermia, altered mental status, hypotension, bradycardia, and 
hypoventilation, the need for thyroid hormone replacement is more emergent 
and treatment can be accomplished with either 100 mg a day of T4 or 25 to 
50 mg a day of T3 administered intravenously. These patients often require 
intensive care unit monitoring with volume repletion, gentle warming, and 
ventilatory support in the face of CO2 retention. Administration of 
hydrocortisone (100 mg q8h) should be undertaken until results of serum 
cortisol testing are obtained. When treated in this manner, hemodynamics 
including systemic vascular resistance, cardiac output, and heart rate 
improve within 24 to 48 hours. 
2.11.0 SUBCLINICAL THYROID DISEASE  
In contrast to overt symptomatic thyroid disease, subclinical thyroid 
disease implies the absence of classic hyperthyroid or hypothyroid related 
symptoms in patients with thyroid dysfunction. The definition has been 
further refined to include the demonstration of an abnormal TSH level in the 
face of normal serum levels of total T4, free T4, total T3 and free T3. [14] [41] 
With the advent of widespread TSH screening, the magnitude of subclinical 
thyroid disease may exceed that of overt disease by threefold to fourfold.[35] 
 
2.11.1 SUBCLINICAL HYPOTHYROIDISM  
Subclinical hypothyroidism defined as a TSH above the upper range 
of the reference population (usually >5 mIU/ml) is seen in up to 9 percent of 
unselected populations, and clearly prevalence increases with advancing 
age.[35] In contrast to younger patients in whom there is a strong female 
predilection, in older populations, this difference is lost. 
 Subclinical hypothyroidism alters lipid metabolism, atherosclerosis, 
cardiac contractility, and systemic vascular resistance. Cholesterol levels rise 
in parallel with increments in TSH elevations starting at 5 mIU/liter. A large 
study of women in Rotterdam showed that atherosclerosis and myocardial 
infarction increased with odds ratios of 1.7 and 2.3 in subclinical 
hypothyroid women, respectively. Interestingly, the presence of antithyroid 
antibodies as a measure of autoimmune thyroid disease indicated heightened 
risk.[36] Restoration of serum TSH to normal after thyroid hormone 
replacement improved lipid levels, lowered systemic vascular resistance, and 
improved cardiac contractility.[41] Patients with subclinical hypothyroidism 
have prolonged isovolumic relaxation times, whereas systolic contractile 
function does not change. Replacement with l-thyroxine sodium at a mean 
dose of 68 mg per day (range 50 to 100 mg per day) restored isovolumic 
relaxation times to normal and when compared with the same patients before 
therapy, systemic vascular resistance declined and systolic function 
significantly improved.[42]  
A variety of studies have indicated that the changes in systemic 
vascular resistance result from alterations in endothelium-dependent 
vasodilation. [11] 22] Taken together, it seems appropriate to recommend 
thyroid hormone replacement for all patients with subclinical 
hypothyroidism from a cardiovascular perspective. The lack of untoward 
cardiac effects observed when serum TSH levels normalize indicate that the 
potential benefits far outweigh the risks of treatment. [2] [11] [34] 
2.11.2 SUBCLINICAL HYPERTHYROIDISM  
Subclinical hyperthyroidism is diagnosed when serum TSH is low 
(<0.1 mIU/ml) and both T4 and T3 are normal.[13] The significance of 
subclinical hyperthyroidism was conclusively established from a study of 
atrial fibrillation in patients 60 years of age or older in the Framingham 
cohort.[43] Prevalence of atrial fibrillation after 10 years was 28 percent in 
the subclinical hyperthyroid patient population compared with 11 percent in 
patients with normal thyroid function with a relative risk of 3.1.  
A large U.S. study of patients 65 years or older confirmed and 
extended this result.[44] A population-based study of more than 1000 
individuals with subclinical hyperthyroidism not receiving l-thyroxine 
therapy or antithyroid medication demonstrated that a TSH level of less than 
0.5 was associated with twofold increased mortality with relative risk of 2.3 
to 3.3 from all causes, which in turn was largely accounted for by increases 
in cardiovascular mortality.[44]
 
 
 
 
 
 
 
 
 
 
 
 
 
            
               3. AIMS AND OBJECTIVES 
1. To study the effects of Hypothyroidism and Hyperthyroidism in CVS 
using 2D Echo (TTE) 
2. To correlate the various Echo dimensions in these disorders with age, sex 
and T4 levels.  
3. To compare the outcome with the international studies. 
 
 
 
 
 
 
 
 
 
 
 
 
                        4. MATERIALS AND METHODS 
 
Duration of study: 6 months 
Period of study: February 2009 to July 2009 
Selection of study subjects: Patients attending Department of Medicine and 
Department of Endocrinology, Government Rajaji Hospital, Madurai with 
Hypothyroidism or Hyperthyroidism 
Number of Patients studied: 50 patients in Hypothyroidism group and 50 
patients in Hyperthyroidism group 
Data Collection: Clinical, Biochemical and Echocardiographic Data. 
Methods: Standard clinical and Laboratory methods. 
Ethical clearance: Obtained  
Consent: Informed consent obtained 
Inclusion Criteria:  
1. Overt or subclinical hypothyroidism 
2. Overt or subclinical hyperthyroidism 
3. Patients presented for the first time with Hypothyroidism or 
Hyperthyroidism 
4. Patients without any other co morbid conditions 
Exclusion criteria: 
1. Hypertension 
2. Diabetes 
3. Coronary Artery Disease  
4. Anemia 
5. Patient already on treatment 
6. Known valvular Heart Disease patients 
7. COPD patients 
8. Age >70years 
9. Pregnancy 
10. Patients taking drugs which could alter the cardiac functions such as beta 
blockers, calcium channel blockers and amiodarone  
Design of Study: Prospective study 
Statistical Tools used: Statistical analysis using EPI-INFO 2002 desinged 
by CDC, Atlanta 
Echo done by: 2D TTE – Aloka Full HD, using 3.5 MHz phased array 
transducer. 
Measurements taken as per the recommendations of the American Society 
for Echocardiography. 
 
                                            
                                              5. RESULTS 
 
Over 50 hypothyroid patients and 50 hyperthyroid patients had been 
selected for study. 2D Trans Thoracic Echo (TTE) done for them. Various 
parameters like LVEF, LV mass, IVS(s), IVS (d), presence of pericardial 
effusion, presence of DCM, MVP were recorded. The parameters were 
analyzed carefully using EPI INFO 2002.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1. Group statistics of Hypothyroidism and Hyperthyroism in our 
study  
 
 GROUP 
N MEAN 
STD. 
DEVIATION 
STD. ERROR 
MEAN 
T TEST ( P 
VALUE) 
HYPOTHYROIDISM 50 32.08 8.383 1.186 AGE 
HYPERTHYROIDISM 50 30.74 5.872 .830 
0.357 
HYPOTHYROIDISM 50 58.46 11.67277 1.65078 LVEF% 
HYPERTHYROIDISM 50 63.12 2.70781 .38294 
0.007*** 
HYPOTHYROIDISM 50 .8820 .19555 .02766 IVS(S) 
HYPERTHYROIDISM 50 .8780 .13893 .01965 
.906 
HYPOTHYROIDISM 50 .7280 .20508 .02900 
HYPERTHYROIDISM 50 .7100 .15419 .02181 
HYPERTHYROIDISM 50 3.1420 .13262 .01876 
IVS(D) 
HYPERTHYROIDISM 50 5.08 .12778 .01807 
.621 
HYPOTHYROIDISM 50 3.72 .30971 .04380 LVID(S) 
HYPERTHYROIDISM 50 3.63 .26128 .03695 
0.120 
HYPOTHYROIDISM 50 5.088 .56266 .07957 LVID(D) 
HYPERTHYROIDISM 50 4.9420 .49820 .07046 
0.173 
HYPOTHYROIDISM 50 124.44 45.39584 6.41994 LV MASS 
INEDEX HYPERTHYROIDISM 50 111.48 34.44857 4.87176 
0.111 
 
 
The p value showed that the variables were comparable within the groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table2. Incidence of DCM in hypothyroidism and hyperthyroidism in 
our study 
 
GROUP 
DCM 
HYPOTHYROIDISM 
HYPERTHYROIDIS
M TOTAL 
CHI 
SQUARE 
ABSENT 41 50 91
DCM PRESENT 9 0 9
TOTAL 50 50 100
0.003***
  
 
9 out of 50 patients in Hypothyroidism group had DCM and none had 
DCM in hyperthyroidism group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table3. Incidence of MVP in the study groups 
 
GROUP MVP 
HYPOTHYROIDISM HYPERTHYROIDISM TOTAL 
COUNT 49 43 92 
% WITHIN GROUP 98.0% 86.0% 92.0% 
 
ABSENT 
% OF TOTAL 49.0% 43.0% 92.0% 
COUNT 1 7 8 
% WITHIN GROUP 2.0% 14.0% 8.0% 
MVP PRESENT 
% OF TOTAL 1.0% 7.0% 8.0% 
COUNT 50 50 100 
% WITHIN GROUP 100.0% 100.0% 100.0% 
TOTAL 
% OF TOTAL 50.0% 50.0% 100.0% 
 
Chi Square Test: p Value-0.29 
 
7 out of 50 patients in Hypothyroidism group had MVP. The 
prevalence was 14% within the group. One patient out of 50 hypothyroid 
patients had MVP; hence the prevalence was 2% within the group. 
 
 
 
 
 
 
 
 
Table 4. Incidence PHT in the study groups  
 
GROUP 
PHT 
HYPOTHYROIDISM
HYPERTHYROIDIS
M TOTAL 
COUNT 41 50 91 
% WITHIN GROUP 82.0% 100.0% 91.0% 
ABSENT 
% OF TOTAL 41.0% 50.0% 91.0% 
COUNT 9 0 9 
% WITHIN GROUP 18.0% .0% 9.0% 
PHT PRESENT 
% OF TOTAL 9.0% .0% 9.0% 
COUNT 50 50 100 
% WITHIN GROUP 100.0% 100.0% 100.0% 
TOTAL 
% OF TOTAL 50.0% 50.0% 100.0% 
 
Chi Square Test: p Value=0.003** 
 
9 out of 50 patients in Hypothyroidism had PHT. This prevalence was 
18% within the group. No one in hyperthyroidism group had PHT. 
 
 
 
 
 
 
 
 
 
Table 5. Incidence of pericardial effusion in the study group 
 
 
GROUP PERICARDIAL EFFUSION 
HYPOTHYROIDISM HYPERTHYROIDISM TOTAL 
COUNT 41 50 91 
% WITHIN GROUP 82.0% 100.0% 91.0% 
ABSENT 
% OF TOTAL 41.0% 50.0% 91.0% 
COUNT 2 0 2 
% WITHIN GROUP 4.0% .0% 2.0% 
MILD EFFUSION 
% OF TOTAL 2.0% .0% 2.0% 
COUNT 7 0 7 
% WITHIN GROUP 14.0% .0% 7.0% 
MODERATE  EFFUSION 
% OF TOTAL 7.0% .0% 7.0% 
COUNT 50 50 100 
% WITHIN GROUP 100.0% 100.0% 100.0% 
TOTAL 
% OF TOTAL 50.0% 50.0% 100.0% 
 
Chi Square Test: p Value=0.007** 
 
9 out of 50 patients with hypothyroidism had Pericardial Effusion. In 
those patients with pericardial effusion 14% had Moderate effusion within 
the group and 4% had mild effusion. 
 
 
 
 
 
 
 
Table 6. Age distribution within Hypothyroidism and Hyperthyroidism  
 
  
GROUP AGE 
HYPOTHYROIDISM HYPERTHYROIDISM TOTAL 
COUNT 1 1 2
% WITHIN GROUP 2.0% 2.0% 2.0%
< 20 YRS 
% OF TOTAL 1.0% 1.0% 2.0%
COUNT 22 20 42
% WITHIN GROUP 44.0% 40.0% 42.0%
20-30 YRS 
% OF TOTAL 22.0% 20.0% 42.0%
COUNT 22 28 50
% WITHIN GROUP 44.0% 56.0% 50.0%
30-40 YRS 
% OF TOTAL 22.0% 28.0% 50.0%
COUNT 2 0 2
% WITHIN GROUP 4.0% .0% 2.0%
40-50 YRS 
% OF TOTAL 2.0% .0% 2.0%
COUNT 3 1 4
% WITHIN GROUP 6.0% 2.0% 4.0%
50-60 YRS 
% OF TOTAL 3.0% 1.0% 4.0%
COUNT 50 50 100
% WITHIN GROUP 100.0% 100.0% 100.0%
TOTAL 
% OF TOTAL 50.0% 50.0% 100.0%
 
Chi Square Test: p Value=0.432  
 
Most of the Hypothyroidism patients were in 20 t0 30 years of age 
distribution (44%) and most of the hyperthyroidism patients were in 30 to 40 
years of age distribution (56%). 
 
 
 
 
Table 7. Sex distribution of patients with PHT in Hypothyroidism  
 
SEX PHT 
F M TOTAL 
COUNT 29 12 41
% WITHIN SEX 80.6% 85.7% 82.0%
ABSENT 
% OF TOTAL 58.0% 24.0% 82.0%
COUNT 7 2 9PRESENT 
% WITHIN SEX 19.4% 14.3% 18.0%
 
 
Out of 9 patients with PHT in hypothyroidism group 7 females and 2 
male patients were present. This gives 19.4% of females and 14.3% of males 
within sex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8.  Sex Distribution of Pericardial Effusion in patients with 
Hypothyroidism 
 
SEX PERICARDIAL EFFUSION 
F M TOTAL 
COUNT 29 12 41
% WITHIN SEX 80.6% 85.7% 82.0%
ABSENT 
% OF TOTAL 58.0% 24.0% 82.0%
COUNT 2 0 2
% WITHIN SEX 5.6% .0% 4.0%
MILD EFFUSION 
% OF TOTAL 4.0% .0% 4.0%
COUNT 5 2 7
% WITHIN SEX 13.9% 14.3% 14.0%
MODERATE  EFFUSION 
% OF TOTAL 10.0% 4.0% 14.0%
COUNT 36 14 50
% WITHIN SEX 100.0% 100.0% 100.0%
TOTAL 
% OF TOTAL 72.0% 28.0% 100.0%
A. GROUP = HYPOTHYROIDISM 
 
Chi Sq Test: p Value=0.666 
 
 Out of 50 patients in hypothyroidism group 9 patients had 
pericardial effusion. 7 of them had moderate effusion. 2 of them had mild 
effusion. Sex distribution wise 5.6% females had mild effusion.13.9% of 
female patients and 14.3% of male patients had moderate effusion within the 
sex distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. Sex distribution of MVP in hyperthyroidism group 
 
SEX MVP 
F M TOTAL 
COUNT 34 9 43
% WITHIN SEX 89.5% 75.0% 86.0%
ABSENT 
% OF TOTAL 68.0% 18.0% 86.0%
COUNT 4 3 7
% WITHIN SEX 10.5% 25.0% 14.0%
PRESENT 
% OF TOTAL 8.0% 6.0% 14.0%
COUNT 38 12 50
% WITHIN SEX 100.0% 100.0% 100.0%
TOTAL 
% OF TOTAL 76.0% 24.0% 100.0%
A. GROUP = HYPERTHYROIDISM 
 
Chi Sq Test: p Value=0.337 
 
Out of 7 patients among 50 hyperthyroidism patients had MVP. 
Hence 25% of male sex distribution was noticed with a female sex 
distribution of 10.5%. 
 
 
 
 
 
 
 
 
Table 10. Correlation various variables with varying T4 level in 
hypothyroidism 
 T4 level LVEF% IVS(s) IVS(d) LV(s) LV mass 
Rho 1.000 -.010 -.229 -.190 -.048 .055
Sig. . .944 .110 .187 .741 .703
T4 level 
N 50 50 50 50 50 50
Rho -.010 1.000 -.386** -.404** -.374** -.195
Sig. .944 . .006 .004 .007 .174
LVEF% 
N 50 50 50 50 50 50
Rho -.229 -.386** 1.000 .976** .555** .305*
Sig. .110 .006 . .000 .000 .031
IVS(s) 
N 50 50 50 50 50 50
Rho -.190 -.404** .976** 1.000 .556** .340*
Sig. .187 .004 .000 . .000 .016
N 50 50 50 50 50 50
Sig. .741 .007 .000 .000 . .081
N 50 50 50 50 50 50
Sig. .112 .096 .003 .005 .001 .224
IVS(d) 
N 50 50 50 50 50 50
Rho .000 -.211 .431** .412** .416** .229
Sig. .999 .142 .002 .003 .003 .109
LVID(s) 
N 50 50 50 50 50 50
Rho -.271 -.201 .361** .343* .549** .042
Sig. .057 .161 .010 .015 .000 .773
LVID(d) 
N 50 50 50 50 50 50
Rho .055 -.195 .305* .340* .249 1.000
Sig. .703 .174 .031 .016 .081 .
LV mass 
index 
N 50 50 50 50 50 50
 
No significant correlation had been found with varying T4 (below or 
above a threshold level to designate hypo or hyperthyroidism) and other 
variables. 
 
Table 11. Correlation of T4 levels with DCM 
 
 
T4 level 
Dilated 
Cardiomyopathy
Correlation Coefficient 1.000 -.081
Sig. (2-tailed) . .495
T4 level 
N 50 50
Correlation Coefficient -.081 1.000
Sig. (2-tailed) .495 .
Kendall's tau_b 
Dilated Cardiomyopathy 
N 50 50
 
No significant correlation had been found between DCM and varying 
T4 below a lower level in hypothyroidism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12. Correlation of T4 levelos with Pericardial Effusion 
 
 
 
T4 level 
Pericardial 
Effusion 
Correlation Coefficient 1.000 -.062
Sig. (2-tailed) . .597
T4 level 
N 50 50
Correlation Coefficient -.062 1.000
Sig. (2-tailed) .597 .
Kendall's tau_b 
Pericardial Effusion 
N 50 50
 
No significant correlation found between T4 level and the grading of 
pericardial effusion after a lower T4 in hypothyroidism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 13. Sex distribution of variables within hypothyroid group  
 SEX 
N MEAN STD. DEVIATION 
STD. ERROR 
MEAN 
T TEST (P VALUE)
FEMALE 38 .8868 .13788 .02237 IVS(S) 
MALE 12 .85 .14460 .04174 
0.43 
FEMALE 38 63.00 2.84747 .46192 LVEF% 
MALE 12 63.5000 2.27636 .65713 
0.540 
FEMALE 38 .7237 .14966 .02428 IVS(D) 
MALE 12 .6667 .16697 .04820 
0.268 
FEMALE 38 111.4211 24.13658 3.91547 LV MASS 
INDEX MALE 12 111.6667 57.67674 16.64984 
0.983 
 
The p value was insignificant in the test, so the sex distribution among 
the variables shown happened to be insignificant. Hence, there was no sex 
dependent alteration of LVEF, IVS(s), IVS (d) or LV mass in 
hypothyroidism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14. Distribution of variables according to age in hypothyroidism 
group 
 
 SUM OF 
SQUARES DF MEAN SQUARE F SIG. 
BETWEEN GROUPS 741.390 4 185.347 1.405 
WITHIN GROUPS 5935.030 45 131.890  
LVEF% 
TOTAL 6676.420 49   
.248 
BETWEEN GROUPS .156 4 .039 1.019 
WITHIN GROUPS 1.718 45 .038  
IVS(S) 
TOTAL 1.874 49   
.408 
BETWEEN GROUPS .156 4 .039 .921 
WITHIN GROUPS 1.905 45 .042  
IVS(D) 
TOTAL 2.061 49   
.460 
BETWEEN GROUPS 10200.517 4 2550.129 1.264 
WITHIN GROUPS 90777.803 45 2017.285  
LV MASS 
INDEX 
TOTAL 100978.320 49   
.298 
A. GROUP = HYPOTHYROIDISM 
 
 
The p value was insignificant. So, there was actually no age 
distribution dependent variation in these variables. Hence, LVEF, IVS(s), 
IVS (d) or LV mass did not vary with variation of age in hypothyroidism in 
our test.  
 
 
 
 
                                               6. DISCUSSION 
 
During a period of six months over 50 hypothyroid patients and 50 
hyperthyroid patients from the Department of Endocrinology and 
Department of Medicine had been studied with 2D TTE. 
Parameters like LVEF, LV mass, IVS(s), IVS(d), presence or absence  
of pericardial effusion, presence or absence  of DCM and presence or 
absence of  MVP were taken into consideration.  
Patients were screened for Hypertension, CAD, DM, Valvular Heart 
Disease and COPD and excluded from the study. The results were carefully 
analyzed using EPI INFO 2002, designed by CDC, Atlanta. 
Whether these parameters were changing with changing levels of T4 after a 
threshold level in hypothyroidism or hyperthyroidism had been analyzed.  
Whether these parameters were changing with age and sex distribution in 
both hypothyroidism and hyperthyroidism group also had been analyzed as 
follows:  
 
 
 
1. Nine out of 50 patients in Hypothyroidism group had DCM. None had 
DCM in the hyperthyroidism group. Hence the prevalence of DCM in the 
hypothyroidism group was 18%. 
Dilated Cardiomyopathy in hypothyroidism had been studied in many 
International and Indian studies. Asymmetrical septal hypertrophy had been 
noticed in so many cases with hypothyroid cardiomyopathy. In a study by 
Reza and AS Abbasi 34% of hypothyroid individuals had DCM (MJ Reza, 
AS Abbasi west J Med. 1975 sep 123(3) 228-230).  
The incidence as well as the severity of cardiomyopathy was correlated with 
T4levels in that study by Reza et al and found to have an inverse 
relationship.  
In our study no such relationship between T4 level and severity of DCM had 
been noticed. 
 2. Seven out of 50 patients in Hyperthyroidism group had MVP. The 
prevalence was 14% within the group (Hyperthyroidism). Only one patient 
in the hypothyroidism group had MVP, hence the prevalence was 2% within 
the hypothyroidism group. 
The prevalence of MVP in hyperthyroidism had been established by many 
studies.  
Channik et al observed that the prevalence of MVP was 41% among 39 
hyperthyroid cases studied.  This was the first study which established a 
relationship between MVP and graves disease.  
In a case control study by Alexander bruman et al (Pub. Br. Heart J. 1985 
53:374-7) a prevalence of 16.3% for MVP found in hyperthyroid patients. 
MVP used to be one of the feature of Hyperthyroidism. (51)   
The association between MVP and Hyperthyroidism had been observed 
especially in Hashimoto’s thyroiditis. (52) 
  3. Nine out of 50 patients in Hypothyroidism group had PHT. Hence the 
prevalence of PHT in hypothyroidism was 18%. None in hyperthyroidism 
group had PHT.  
But in a study by Hassan M.Ismail (J.Gen.Int.Medicine 2007 Jan 22(1) 
148-150), the prevalence of PHT was higher with hyperthyroidism than 
hypothyroidism. 
 
4. Nine out of 50 patients with hypothyroidism had pericardial effusion. 
Hence the prevalence of pericardial effusion in the hypothyroidism group 
was 18%. That was very significant. In those patients with pericardial 
effusion 14% had moderate effusion within the group and 4% had mild 
effusion.  
But no one had massive effusion or tamponade in our study, But in a case 
control  study done by  MJ Reza et al  30% to 80% of hypothyroidism 
patients  had pericardial effusion and up to 50% of them developed 
tamponade.  
5. Most of the Hypothyroidism patients were found in the 20 to 40 years age 
distribution (44%), and most of the hyperthyroidism patients were found in 
the 30 to 40 years age distribution (56%).  
6. Out of 50 patients in the hypothyroidism group 9 patients had PHT and 
the prevalence was 18% for PHT in hypothyroidism group. Among them 7 
were females (19.4% within sex distribution). Predominant female sex 
distribution for PHT in hypothyroidism was observed. 
 
7. Out of 50 patients in the hypothyroidism group, 9 had pericardial effusion. 
Seven of them had moderate effusion and 2 of them had mild effusion. Sex 
distribution wise 5.6% female patients had mild effusion and 13.9% of 
female patients 14.3% of male patients had moderate effusion. Though 
pericardial effusion was predominant among female patients, male patients 
were having more severe effusion than female patients. A study by Reza et 
al concluded that there was an observed 1.4:1 female preponderance in 
developing pericardial effusion in hypothyroidism but the ratio used to vary 
in different studies.  
8. No significant correlation had been found between varying   T4 level 
(below or above a level to designate hypo or hyperthyroidism) and other 
parameters.  
Hence the T4 level and development of complications happened to be an all 
or none phenomenon. Rawat B et al also observed that there was no 
significant difference in various diameters among different groups in 
hypothyroidism in a case control study  
But in most of the International studies, we had come across a definite 
relationship between the variation of the T4 level and severity of DCM, 
septal thickness, hypokinesia etc., May be that was due to the prolonged 
latent period between the onset of deficiency to detection of cardiovascular 
abnormalities and the linear relationship with time might had  been 
misinterpreted. More over our study population were fresh cases rather than 
treated or partially treated cases. 
9. No significant correlation had been found between DCM and varying T4 
level, below a lower level in hypothyroidism.  So, once the Thyroxine 
started decreasing the adverse cardiovascular effects were ignited and started 
smoldering unless Thyroxine reintroduced. As we construed above that was 
due to increased interval between onset of the deficiency to the overt clinical 
symptoms or screening interval which might have influenced the severity of 
the lesion rather than the varying hormone level (below a lower level). 
10. No significant correlation found between T4 level and the grading of 
pericardial effusion after a lower T4 level in hypothyroidism. The all or none 
phenomena of T4 level could be considered here also. 
So, in our study in the Hypothyroidism group, 18% of patients had 
Pericardial Effusion and 18% had Dilated Cardiomyopathy. They were all 
symptomatic.  
 Female patients out number male patients in developing complications in 
Hypothyroidism. 
Patients with Hyperthyroidism had MVP with grade I or II MR, they were 
asymptomatic in our study and found incidentally.  
11. The p value was insignificant while testing for the distribution of sex 
dispersion in LVEF, IVS(s), IVS (d) or LV mass in hypothyroidism. Hence 
there was no sex dependent alteration of LVEF, IVS(s), IVS (d) or LV mass 
in hypothyroidism. 
 But anyway the incidence of Hypothyroidism/Hyperthyroidism and 
development of complications were prevalent in female patients when 
compare to male patients. 
12. The p value was insignificant while testing the age distribution in LVEF, 
IVS (s), IVS (d) or LV mass. So, there was actually no age distribution 
dependent variation in these variables. Hence, LVEF, IVS(s), IVS (d) or LV 
mass did not vary with variation of age (in hypothyroidism group )in our 
test. In a study from  Kathmandu by Rawal B and Satyal A (Kathmandu 
University Medical Journal 2003 vol.2, No.3, issue 7, 182-187) and in a 
study by  Bernnet et al (1983), Lee et al(1990) and Bernstein et al (1995) 
concluded that there was increased septal thickness in elderly and it was due 
to age related thickness of the IVS superimposed by the changes induced by 
hypothyroidism. 
  
 
 
 
 
 
 
 
 
 
        
                                            7. CONCLUSION 
• From our study we have come to know that significant percentage of 
patients with hypothyroidism developed various cardiovascular 
morbidities like DCM and pericardial effusion, moreover the level of 
T4 below a lower threshold level in hypothyroidism does not 
influence the severity of DCM or pericardial effusion or chamber size.  
• Out of 50 hypothyroid patients 9 patients had DCM and 9 patients had 
pericardial effusion. The patients with DCM had moderate to severe 
LV dysfunction. They were all symptomatic. 
• Out of 50 hyperthyroid patients 7 patients had MVP with mild MR. 
they were asymptomatic and detected incidentally during screening.  
• No age related increase in severity of LV dysfunction noticed in our 
study. The main influence was by the hypothyroid status per se.  
• The study outcome emphasized the importance of non ischemic 
causes like hypothyroidism in causing DCM and LV dysfunction. 
• The outcome made us to think about the sub clinical hypothyroidism 
where the overt clinical manifestations would not occur and the 
underlying cardiac malfunctions started smoldering. 
• As most of the cardiac morbidities are reversible after treatment, one 
has to screen for thyroid status of the patient while evaluating cases of 
DCM, pericardial effusion and MVP to institute an early rescue. 
• Apart from these anatomical and functional alterations, 
hypothyroidism increases the likelihood of CAD through its pro 
atherogenic effect. 
• So, early detection and treatment of thyroid deficiency plays a vital 
role in preventing this malfunctions to go to an irreversible state. 
• Moreover hyperthyroidism is an important cause of non rheumatic 
atrialfibrillation. 
• It is worthwhile to screen for thyroid status in patients with CAD and 
in all young patients with hypercholesterolemia.  
• Otherwise, the prevalence of  thyroid disorders in tropical countries 
like India act synergistically with other factors like urbanization and 
changing food habits and smoking, in increasing cardiovascular 
morbidity and mortality. 
• Another point to ponder is the prevalence of hypothyroidism and its 
complications in female sex, made it mandatory to screen for thyroid 
deficiency in all women with CAD, pericardial effusion or 
cardiomyopathy. 
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A PROSPECTIVE ECHOCARDIOGRAPHIC STUDY IN PATIENTS  
           WITH   HYPOTHYROIDISM AND HYPERTHYROIDISM 
 
 
Name:     Age:         Sex: 
 
Address:   
 
 
 
 
Symptoms: 
Palpitation        Chest Pain       Dyspnea     NYHA class: 
 
Fatigue   Somnolence Cold/Heat intolerance Tremor Fever 
 
Giddiness   Syncope Goitre 
 
 
Co morbid Conditions: 
 
 
Personal H/O: 
 
Smoker  Alcoholic  Exposure to STD 
 
Menstrual/Obstetric H/O: 
 
General Examinations: 
 
Pulse  BP  Anemia Pedal edema  
CVS: 
 
JVP 
S1  S2  Murmur 
 
Laboratory Analysis: 
 
Hb%  TC  DC- P  L  E  M  ESR  
 
Blood Sugar           Urea       Sr.Creatinine  
  
T3        T4          TSH  
 
ECG in all leads:    
 
A PROSPECTIVE ECHOCARDIOGRAPHIC STUDY IN PATIENTS  
           WITH   HYPOTHYROIDISM AND HYPERTHYROIDISM 
 
 
 
2D ECHOCARDIOGRAM 
 
LV function     LVID(s)                     LVID(d)                      LVEF    % 
 
Stroke Volume 
 
Wall Thickness  IVS(s)                      IVS(d)            LV(s)       LV(d)     
 
Pericardial Effusion            Mild      Moderate     Severe  
 
Wall Motion Abnormalities    Hypokinesia       Akinesia      Dyskinesia 
 
IV Paradoxical Movement      a           b              c 
 
Valves                         Stenosis                              Regurgitation 
Mitral       
Tricuspid Pulmonary 
Aortic 
Pulmonary HT                   TRPG 
Impression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
IP no.- In patients Number 
NYHA- New York Heart Association 
TSH-Thyroid Stimulating Hormone 
T4- Thyroxine 
T3-Tri iodo thyronine 
TTE- Trans Thoracic Echocardiography 
RWMA-Regional Wall Motion Abnormalities 
LVEF- Left Ventricular Ejection Fraction 
LV mass-Left Ventricular Mass 
 IVSD-Inter Ventricular Septal Diameter 
(s)-in systole, (d)- in diastole 
PE-Pericardial Effusion 
MR-Mitral Regurgitation 
MVP-Mitral Valve Prolapse 
PHT- Pulmonary Hypertension 
PR-Pulmonary Regurgitation 
TR-Tricuspid Regurgitation 
DCM-Dilated Cardiomyopathy 
AIIMS-All India Institute of Medical Sciences 
 
 
 Figure1. Incidence of Cardiomyopathy in hypothyroidism and 
hyperthyroidism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.Incidence of MVP in study groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Incidence of PHT in the study groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Incidence of Pericardial Effusion in the study group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Age distribution within hypothyroidism and hyperthyroidism 
group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Sex distribution of PHT in hypothyroidism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Sex distribution of DCM in hypothyroidism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Correlation of T4 levels with LV mass 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Correlation of T4 level with Pericardial Effusion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure10. Correlation of T4 levels with DCM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Distribution of LV Mass according to age in hypothyroidism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Echo Picture 1. DCM in a hypothyroid female 
 
 
 
 
 
 
 
 
Echo Picture 2.Mitral Regurgitation /DCM in a hypothyroid female 
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1 38978 22 F 21.6 0.4 >150 Hypo 64 90/70 II 62 0.7 0.5 112 No No No No No No NO No  
2 43567 36 F 24 0.46 100 Hypo 60 90/60  III 30 1.2 1 190 Yes Gr I No 
TR 
+ 
PR 
+ 
PHT 
+ 40 Mild  + 
3 39545 32 M 22 1.53 62 Hypo 72 118/70 I 65 1.3 1.1 220 Yes 
MR 
+ No 
TR 
+ 
PR 
+ 
PHT 
+ 35 Mod  + 
4 38497 32 M 22 1.53 62 Hypo 60 110/70  I 60 1 0.9 90 No No No No No No NO No  
5 41451 22 M 82 3 >120 Hypo 70 100/70  II 60 0.8 0.6 89 No No No No No No NO No  
6 45434 22 F 15.4 <.70 65.4 Hypo 64 100/80 II 65 0.9 0.7 115 No No No No No No NO No  
7 43654 34 M 54 1.2 88.7 Hypo 68 110/80 II 62 1 0.8 140 No No No No No No NO No  
8 44234 32 F 18 <.80 >150 Hypo 60 90/70 I 65 0.9 0.7 90 No No No No No No NO No  
9 45323 26 M 84 2.5 >150 Hypo 70 100/70 II 60 0.9 0.7 87 No No No No No No NO No  
10 43356 32 F 24 5 49.4 Hypo 70 120/90 I 67 0.7 0.5 92 No No No No No No NO No  
11 47435 23 F 16.8 <.50 >100 Hypo 60 110/70 I 65 0.6 0.5 112 No No No No No No NO No  
12 43434 53 M 34 2.09 20 Hypo 60 120/80 II 60 0.8 0.7 160 No No No No No No NO No  
13 43335 30 F 45.3 0.16 114 Hypo 76 130/80 I 65 1 0.9 150 No No No No No No NO No  
14 43543 40 F 20.3 <.60 >150 Hypo 58 90/60 III 35 1.1 1.3 210 Yes Gr II  
TR 
+ 
PR 
+ 
PHT 
+ 40 Mod + 
15 45232 54 F 50 0.18 >100 Hypo 80 90/70  III 30 1.3 1.1 190 Yes Gr.II No TR+ PR+ 
PHT 
+ 30 Mild  + 
16 45123 30 F 81 10.2 50 Hypo 64 110/70 I 60 1 0.9 78 No No No No No No NO No  
17 42232 28 M 52 0.2 >120 Hypo 62 90/70  III 25 0.9 0.7 291 No Gr II  No 
TR 
+ PR+ PHT+ 35 Mod  + 
18 34452 33 M 16.3 <.30 78 Hypo 64 120/70 I 67 0.9 0.7 112 No No No No No No NO No  
19 34542 32 F 0.2 <15 110 Hypo 60 110/70 II 65 0.7 0.5 87 No No No No No No NO No  
20 35123 34 M 15 4.25 99.5 Hypo 72 110/70 II 65 0.6 0.5 114 No No No No No No NO No  
21 34654 30 F 0.1 0.5 150 Hypo 70 120/70 II 60 0.6 0.5 90 No No No No No No NO No  
22 43435 36 F 22.5 18 48.4 Hypo 64 110/60 I 60 0.7 0.5 89 No No No No No No NO No  
23 34453 30 M 20 2.7 >100 Hypo 60 112/74 II 64 0.9 0.7 115 No No No No No No NO No  
24 45233 34 F 40.4 1.2 >150 Hypo 72 90/70  III 30 1 0.9 140 No Gr I  No TR+ PR+ 
PHT 
+ 40 Mod + 
25 46544 24 F 0.2 0.7 100 Hypo 64 112/60 II 65 1 0.9 90 No No No No No No NO No  
 
 
Hypoyhyroidism group contd… 
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26 48456 25 F 53 0.15 62 Hypo 70 100/70 I 60 0.9 0.7 87 No No No No No No NO No  
27 45567 26 F 17.3 <.70 87.4 Hypo 64 100/70 II 60 0.9 0.7 92 No No No No No No NO No  
28 45654 25 F 23.5 0.6 88.72 Hypo 74 110/80 I 65 0.9 0.7 112 No No No No No No NO No  
29 47125 22 F 16 2 100 Hypo 60 120/80 II 62 0.9 0.7 160 No No No No No No NO No  
30 42456 35 F 83 3 >150 Hypo 64 100/80 II 65 0.7 0.5 150 No No No No No No NO No  
31 43543 23 F 25 2.5 >120 Hypo 68 120/70 I 60 0.6 0.5 98 No No No No No No NO No  
32 45564 29 F 17 0.8 50 Hypo 60 90/70 II 67 0.6 0.5 95 No No No No No No NO No  
33 43653 34 M 42 0.16 >100 Hypo 70 100/70 II 65 0.7 0.5 78 No No No No No No NO No  
34 45433 50 F 20 <.70 >150 Hypo 58 90/70  III 30 1.2 1 200 Yes MR + No 
TR 
+ 
PR 
+ 
PHT 
+ 40 Mod + 
35 36876 36 F 54 0.19 48.2 Hypo 70 120/70 II 65 1 0.9 90 No No No No No No NO No  
36 37344 23 F 16.23 <.60 >100 Hypo 72 130/90 II 65 1 0.9 87 No No No No No No NO No  
37 36452 33 F 54 2 >150 Hypo 60 90/70  III 34 1.3 1.1 198 No 
Gr I 
MR No 
TR 
+ 
PR 
+ 
PHT 
+ 35 Mod + 
38 37356 25 F 14 <.15 114 Hypo 64 100/70 I 60 0.9 0.7 112 No No No No No No NO No  
39 35445 19 F 21 <.30 100 Hypo 62 120/90 II 67 0.7 0.5 160 No No No No No No NO No  
40 46322 34 F 23 1.54 62 Hypo 64 100/70 II 65 0.6 0.5 150 No No No No No No NO No  
41 43535 29 F 35 1.2 80.2 Hypo 80 90/70 I 65 0.8 0.7 98 No No No No No No NO No  
42 46335 35 M 25 0.2 >110 Hypo 70 110/80 I 60 1 0.9 95 No No No No No No NO No  
43 44564 38 M 16.4 <.50 >100 Hypo 76 130/80 II 60 0.8 0.6 78 No No No No No No NO No  
44 33446 54 F 0.3 0.2 150 Hypo 60 100/70 I 64 0.9 0.7 89 No No No No No No NO No  
45 35322 35 F 0.23 0.12 112 Hypo 70 120/80 II 60 1 0.9 112 No No No No No No NO No  
46 46332 45 F 40 2.1 >100 Hypo 60 130/80 II 60 0.9 0.7 150 No No No No No No NO No  
47 47337 24 F 16 0.8 >150 Hypo 68 110/80 II 65 1.2 1 142 Yes 
Gr II 
MR + No 
TR 
+ 
PR 
+ 
PHT 
+ 40 Mod  + 
48 45526 26 M 34 1.53 48.7 Hypo 60 100/70 I 62 0.7 0.5 98 No No No No No No NO No  
49 35746 38 F 25.6 2 >100 Hypo 72 120/80 II 65 0.6 0.5 98 No No No No No No NO No  
50 34347 40 F 150 12.8 0.32 Hyper 112 110/70 II 60 0.8 0.7 140 No No No No No No NO No  
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1 39786 33 F 158 13.5 0.1 Hyper 150 110/70 II 67 1 0.9 112 No 
Tri 
MR 
MVP 
+ No No No NO No  
2 45672 28 F 89.3 12 0.02 Hyper 100 130/90 I 65 0.8 0.7 87 No No No No No No NO No  
3 39545 37 F 112 14.8 0.1 Hyper 120 120/80 II 60 0.9 0.7 114 No No No No No No NO No  
4 38976 22 M 200 15 0.004 Hyper 114 110/70 II 65 0.9 0.7 90 No No No No No No NO No  
5 44515 34 M 160.8 15.3 0.008 Hyper 130 120/80 II 65 0.7 0.5 89 No 
Tri 
MR MVP+ No No No NO No  
6 44345 22 M 156.8 14.3 0.05 Hyper 120 130/90 II 60 0.7 0.5 115 No No No No No No NO No  
7 46543 18 F 159 15.4 0.04 Hyper 114 112/78 I 60 0.6 0.5 140 No No No No No No NO No  
8 42346 32 F 150 11.8 0.32 Hyper 112 120/80 II 67 0.7 0.5 90 No No No No No No NO No  
9 43234 29 F 162.7 12.4 0.04 Hyper 128 120/80 I 65 0.9 0.7 87 No 
Tri 
MR 
MVP 
+ No No No NO No  
10 43562 34 M 156 13.6 0.2 Hyper 120 110/70 I 65 1 0.9 92 No No No No No No NO No  
11 44356 35 F 160 14.8 0.28 Hyper 130 140/90 II 60 1 0.9 112 No No No No No No NO No  
12 44342 23 F 152.8 12.5 0.042 Hyper 128 112/80 I 60 0.9 0.7 160 No No No No No No NO No  
13 43352 35 F 154.9 13.4 0.32 Hyper 132 120/80 II 64 0.9 0.7 150 No No No No No No NO No  
14 45432 22 F 156 14.2 0.3 Hyper 140 112/70  II 67 0.7 0.5 98 No No No No No No NO No  
15 42324 32 F 154.2 13.4 0.024 Hyper 100 110/70 I 65 0.6 0.5 95 No No No No No No NO No  
16 41234 30 F 162.4 15.6 0.23 Hyper 124 130/90 i 60 0.8 0.7 78 No No No No No No NO No  
17 42321 35 F 158 14.3 0.34 Hyper 132 120/80 I 65 1 0.9 140 No No No No No No NO No  
18 34523 28 F 153.6 15 0.22 Hyper 132 110/70 II 65 0.8 0.7 90 No No No No No No NO No  
19 35423 32 F 165.2 16.7 0.34 Hyper 130 120/86 II 60 0.9 0.7 87 No 
Gr I 
MR MVP+ No No No NO No  
20 31234 28 F 154.7 15.6 0.26 Hyper 134 120/70 II 60 1 0.9 92 No No No No No No NO No  
21 36543 34 F 152 16 0.32 Hyper 128 130/90 I 67 0.9 0.7 112 No No No No No No NO No  
22 43521 32 M 156.3 15.8 0.28 Hyper 136 112/80 II 65 0.9 0.7 112 No No No No No No NO No  
23 44332 32 M 154 15.8 0.33 Hyper 140 130/90 II 65 0.7 0.5 87 No No No No No No NO No  
24 42334 26 F 160 16.4 0.28 Hyper 128 120/70 II 60 0.9 0.7 114 No No No No No No NO No  
25 45445 35 F 156 15.7 0.34 Hyper 126 110/70 I 60 0.8 0.6 90 No 
Tri 
MR 
MVP 
+ No No No NO No  
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26 44567 35 F 150 15 0.33 Hyper 112 110/70 II 64 0.9 0.7 89 No No No No No No NO No  
27 45673 28 F 152.8 12.8 0.32 Hyper 120 120/80 I 60 1 0.9 115 No No No No No No NO No  
28 46543 22 F 154.3 13.5 0.1 Hyper 100 130/90 II 60 1.1 0.9 140 No No No No No No NO No  
29 41256 36 F 162.4 12 0.004 Hyper 120 120/86 II 65 0.9 0.7 90 No No No No No No NO No  
30 44563 33 M 165.7 14.8 0.006 Hyper 114 130/70  II 62 0.7 0.5 87 No 
Tri 
MR 
MVP 
+ No No No NO No  
31 45432 32 F 200 14 0.05 Hyper 112 120/80 II 65 1.1 0.9 92 No No No No No No NO No  
32 46554 22 F 1445 15.2 0.33 Hyper 150 140/80 II 65 1 0.9 112 No No No No No No NO No  
33 46654 34 F 165 15 0.2 Hyper 128 130/90 I 65 0.7 0.5 160 No No No No No No NO No  
34 44334 22 F 150 14.2 0.05 Hyper 130 128/74 II 60 0.7 0.5 150 No No No No No No NO No  
35 38765 32 F 167.8 14 0.28 Hyper 128 120/90 II 60 0.9 0.7 98 No No No No No No NO No  
36 33446 26 F 200 14.5 0.024 Hyper 100 120/70 I 67 0.9 0.7 95 No No No No No No NO No  
37 34523 32 M 150 12.8 0.34 Hyper 124 124/78 I 65 1 0.9 78 No No No No No No NO No  
38 33554 32 M 158 14.8 0.23 Hyper 132 130/90 II 65 1.1 0.9 291 No No No No No No NO No  
39 34454 53 F 90 13.4 0.22 Hyper 130 120/90 II 60 0.9 0.7 112 No No No No No No NO No  
40 43225 30 F 112 15 0.28 Hyper 134 130/90 I 60 0.7 0.5 150 No No No No No No NO No  
41 43352 40 F 200 16.7 0.33 Hyper 136 140/90 I 65 1.1 0.9 142 No No No No No No NO No  
42 43354 28 F 160.8 13.6 0.28 Hyper 124 120/80 II 60 1 0.9 98 No No No No No No NO No  
43 45543 33 M 156 13.4 0.34 Hyper 120 124/76 I 60 0.7 0.5 98 No No No No No No NO No  
44 34442 32 F 162.4 14.4 0.02 Hyper 124 120/80 II 64 0.7 0.5 140 No No No No No No NO No  
45 33221 34 F 160.5 16 0.1 Hyper 112 130/90 II 67 0.9 0.7 112 No No No No No No NO No  
46 43322 30 F 158 15.5 0.004 Hyper 120 120/70 II 65 1.1 0.9 87 No No No No No No NO No  
47 45332 36 F 153.6 16.3 0.04 Hyper 126 110/70 I 60 1 0.9 114 No No No No No No NO No  
48 43521 28 F 154.8 14.3 0.32 Hyper 112 120/80 II 65 1 0.9 90 No No No No No No NO No  
49 35544 24 M 154 16.4 0.027 Hyper 130 112/80 I 65 0.9 0.7 89 No 
Gr I 
MR MVP No No No NO No  
50 33445 35 M 148.3 15.2 0.23 Hyper 134 120/80 I 60 0.9 0.7 112 No No No No No No NO No  
 
